Drug intelligence / Profile preview

DGT-BLC-Cancer2

Development stage: Preclinical
Lead developer: dGenThera
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
Administration: Intravenous

Overview

DGT-BLC-Cancer2 is a discovery-stage targeted radiotherapeutic being developed by dGenThera. It is part of the company's bioligand-tag conjugate (BLC) platform, which is designed to deliver radioactive isotopes directly to tumor cells by targeting specific cell-surface receptors. This particular asset is currently in the discovery phase for an undisclosed oncological indication designated as 'Cancer 2.' The platform aims to improve the therapeutic index of radiotherapy by minimizing off-target exposure while maximizing dose delivery to the tumor site.

Beyond the preview

Go deeper on DGT-BLC-Cancer2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DGT-BLC-Cancer2.

Explore the full profile